Immix Biopharma (IMMX) Cash from Investing Activities (2021 - 2026)
Immix Biopharma (IMMX) reported Cash from Investing Activities of -$4.8 million for Q1 2026, down 6989.98% on a YoY basis from $69678.6 in Q1 2025, and up 27.76% sequentially from -$6.6 million in Q4 2025.
Immix Biopharma (IMMX) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Immix Biopharma (IMMX) has 5 years of Cash from Investing Activities data on file, last reported at -$4.8 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities fell 6989.98% year-over-year to -$4.8 million; the trailing twelve-month figure through Mar 2026 stood at -$11.9 million (down 1166.26% YoY), and the FY2025 full-year result was -$7.2 million, down 512.54% from the prior year.
- Cash from Investing Activities advanced to -$4.8 million in Q1 2026, from -$6.6 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$13177.0 in Q4 2023 to a low of -$6.6 million in Q4 2025.
- A 4-year average of -$1.3 million and a median of -$286727.5 in 2024 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities soared 77.57% in 2025 and tumbled 6989.98% in 2026, its largest moves.
- Tracing IMMX's Cash from Investing Activities over 4 years: stood at -$13177.0 in 2023, then sank by 3748.76% to -$507151.0 in 2024, then tumbled by 1210.46% to -$6.6 million in 2025, then advanced by 27.76% to -$4.8 million in 2026.
- Business Quant data shows IMMX's Cash from Investing Activities at -$4.8 million in Q1 2026, -$6.6 million in Q4 2025, and -$372456.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 172.62 Mn |
| 10 | Immix Biopharma | 473.68 Mn | 473.68 Mn | - | -4.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.80 Mn |
| Mar 31, 2026 | -4.80 Mn |
| Dec 31, 2025 | -6.65 Mn |
| Dec 31, 2025 | -6.65 Mn |
| Sep 30, 2025 | -372,456.00 |
| Sep 30, 2025 | -372,456.00 |
| Jun 30, 2025 | -127,630.00 |
| Jun 30, 2025 | -127,630.00 |
| Mar 31, 2025 | -67,713.00 |
| Mar 31, 2025 | -67,713.00 |
| Dec 31, 2024 | -507,151.00 |
| Dec 31, 2024 | -507,151.00 |
| Sep 30, 2024 | -271,542.00 |
| Sep 30, 2024 | -271,542.00 |
| Jun 30, 2024 | -97,074.00 |
| Jun 30, 2024 | -97,074.00 |
| Mar 31, 2024 | -301,913.00 |
| Mar 31, 2024 | -301,913.00 |
| Dec 31, 2023 | -13,177.00 |
| Dec 31, 2023 | -13,177.00 |